Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05530408 |
| Other study ID # |
STUDY00148295 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 24, 2022 |
| Est. completion date |
May 31, 2028 |
Study information
| Verified date |
May 2024 |
| Source |
University of Kansas Medical Center |
| Contact |
Cristal Monge |
| Phone |
9135882473 |
| Email |
chernandez[@]kumc.edu |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The goal of this project is to establish a registry and biorepository of images and
biological samples from subjects undergoing novel pulmonary imaging methods to be used for
future research aimed toward identifying clinical applications of imaging methods and toward
understanding the physiological significance of imaging biomarkers. This registry and
biorepository will accelerate the development of these imaging techniques and may lead toward
future clinical adoption of quantitative pulmonary imaging.
Description:
Imaging is increasingly used for the non-invasive assessment of pulmonary health. Alongside
this increased usage, there is enhanced interest in quantitative imaging methods that provide
robust, repeatable, and objective measures of lung structure and function. At the forefront
of this effort is quantitative computed tomography (qCT). CT imaging is the gold standard for
high-resolution imaging of pulmonary structure, and the underlying physics of CT imaging is
highly amenable to quantitative analysis.
In addition to qCT, MRI is garnering increased interest as a modality for pulmonary imaging.
Like CT, MRI is non-invasive, and it has the additional advantage of being ionizing
radiation-free, making it more suitable for repeat imaging and for use in pediatric patients.
Traditionally, MRI was not often used for lung imaging due to several difficulties regarding
the acquisition of quality images in the lungs. However, recent advances to pulmonary MRI
methods have enabled the acquisition of high-quality images of pulmonary structure and
function. These advances include the use of ultra-short and zero echo time (UTE and ZTE,
respectively) MRI methods, as well as the use of gaseous contrast agents such as
hyperpolarized 129Xe.
Despite these advances in qCT and MRI methods, the clinical applications for these imaging
techniques are often unclear. Moreover, as new techniques, many of the imaging biomarkers in
use have been independently developed by multiple sites and thus require standardization. As
such, there is an urgent need both to standardize imaging/analysis techniques and to
determine optimal clinical applications for these novel quantitative imaging methods.
